Our Expert Network

  1. Why RNAi-Based Oncology Must Move Beyond Single-Target Thinking 5/29/2026

    RNAi therapeutics may help oncology move beyond single-target drugs by disrupting adaptive tumor survival networks driving resistance in solid tumors.

  2. What Makes An RNA Platform Investable? Lessons From The Last Wave Of Biotech Financing 5/28/2026

    RNA investing has shifted from hype to scalability, forcing companies to prove manufacturability, delivery strength, and platform-wide value.

  3. RNA Manufacturing Foundations: From DNA Templates To In Vitro Transcription (Pt. 1) 5/27/2026

    Cell-free RNA production is reshaping biomanufacturing through modular IVT workflows, advanced capping strategies, and scalable DNA template design.

  4. Beyond Hairpins: A New Translational Repression Assay Expands RNA-Binding Protein Research 5/26/2026

    Researchers expanded translational repression assays beyond RNA hairpins, enabling scalable study of linear RNA-protein interactions in living cells.

  5. Engineering RNA Payload Distribution In LNPs To Unlock Higher In Vivo Gene Editing Efficiency 5/22/2026

    New research shows RNA payload distribution inside LNPs — not just encapsulation efficiency — may be key to unlocking stronger in vivo gene editing performance.

  6. Beyond Guanidine: Scientists Discover A Mysterious Riboswitch Variant With A Different Biological Target 5/22/2026

    Scientists identified a mysterious riboswitch variant that resembles guanidine sensors but likely evolved to detect an entirely different metabolite.

  7. RNA Modification-Mediated Translational Control In Immune Cells 5/20/2026

    Exploring how m6A RNA modifications control immune cell translation, influencing inflammation, tumor immunity, T cell activation, and future immunotherapies.

  8. Repeating Sanofi's Ballroom Design On Two Continents 5/15/2026

    Moveable walls and a stunning number of robotics at its sites in France and Singapore, among other features, has earned Sanofi international recognition for innovation.

  9. Validation Of A RIG-I–Based Functional Assay For Quantitative Detection Of Double-Stranded RNA Impurities In mRNA Drug Substance 5/13/2026

    A validated RIG-I assay adds a biology-informed layer to dsRNA testing by quantifying immunogenic impurities in IVT-derived mRNA therapeutics for deeper functional insight.

  10. Suppressor tRNA Therapeutics: A New Frontier In Treating Genetic Disease 5/8/2026

    Suppressor tRNAs could unlock a scalable new way to treat genetic diseases caused by nonsense mutations, restoring full-length proteins across multiple indications.